Citadel Advisors
MRKR icon

Citadel Advisors’s Marker Therapeutics MRKR Stock Holding History

Citadel Advisors’s Portfolio MRKR Stock Details MRKR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-1,750
Closed -$6K – 13239
2022
Q2 		$6K Sell
1,750
-380
-18% -$1.26K ﹤0.01% 12666
2022
Q1 		$9K Sell
2,130
-7,230
-77% -$41.3K ﹤0.01% 13386
2021
Q4 		$89K Buy
9,360
+4,480
+92% +$59.5K ﹤0.01% 12830
2021
Q3 		$82K Sell
4,880
-4,700
-49% -$96.3K ﹤0.01% 13053
2021
Q2 		$267K Sell
9,580
-1,490
-13% -$39.2K ﹤0.01% 11551
2021
Q1 		$248K Buy
11,070
+7,710
+229% +$176K ﹤0.01% 11251
2020
Q4 		$49K Buy
3,360
+600
+22% +$9.31K ﹤0.01% 10571
2020
Q3 		$41K Buy
2,760
+480
+21% +$8.76K ﹤0.01% 9671
2020
Q2 		$47K Buy
2,280
+1,120
+97% +$24.5K ﹤0.01% 9334
2020
Q1 		$22K Buy
+1,160
New +$29.6K ﹤0.01% 9275
2019
Q4 		– Sell
-9,380
Closed -$479K – 9503
2019
Q3 		$479K Buy
9,380
+7,730
+468% +$457K ﹤0.01% 6832
2019
Q2 		$131K Buy
+1,650
New +$98K ﹤0.01% 8419
2019
Q1 		– Sell
-1,750
Closed -$97K – 9651
2018
Q4 		$97K Sell
1,750
-1,060
-38% -$77.3K ﹤0.01% 8252
2018
Q3 		$254K Buy
+2,810
New +$241K ﹤0.01% 7844

Other funds holding MRKR

NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $665M AUM 95.48% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
ACM
Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
LPL Financial
LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return
CIA
Concurrent Investment Advisors Tampa, Florida $11.8B AUM 31.86% 1-Year Est. Return

Citadel Advisors's MRKR Position: Q2 2026 in Review

Citadel Advisors opened a new position in Marker Therapeutics (MRKR) in Q2 2026: 32,517 shares worth $47.8K. The stake represents ﹤0.01% of the portfolio and ranks #13135 among its holdings. This is a return to the name: Citadel Advisors previously reported a position in MRKR as recently as Q4 2025.

Citadel Advisors first reported a position in MRKR in Q3 2019 and has held it in 13 quarters since. The position peaked at $817K in Q2 2021. 35 funds tracked by Wall St. Rank hold MRKR as of Q2 2026.

  • Citadel Advisors held 32,517 shares of Marker Therapeutics worth $47.8K as of Q2 2026.
  • Marker Therapeutics was a new Citadel Advisors position in Q2 2026.
  • Marker Therapeutics made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #13135 holding.
  • Citadel Advisors first reported a position in Marker Therapeutics in Q3 2019 and has held it in 13 quarters since.
  • Citadel Advisors's Marker Therapeutics position peaked at $817K in Q2 2021.
  • 35 funds tracked by Wall St. Rank held Marker Therapeutics as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.